A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

This study is for adults, aged 18 and over, who have a specific type of blood cancer called Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukaemia (CML) in the chronic phase.

To be considered, your body's organs need to be working well. If you have Ph+ CML, you might be eligible if you've already tried at least two other types of treatments (called tyrosine kinase inhibitors or TKIs) for your cancer, but they either stopped working or caused side effects you couldn't tolerate. Your doctor would help decide if this study is a good option for you based on this.

There are some reasons why you might not be able to join. For instance, if your CML is in a more advanced stage (called accelerated or blast phase), or if you've already had a very similar type of treatment to KQB198. Also, if you have certain bowel problems, serious heart issues, or a lung condition called interstitial lung disease, you wouldn't be able to take part. It's important that your body can absorb the study medicine properly.

If you join this study, you would take the medicine KQB198 every day. Sometimes it's given alone, and sometimes it's given साथ with another cancer medicine. During the first eight weeks, you'd have about eight clinic visits. After that, you'd visit the clinic less often, typically once a month (every four weeks). These visits are to check how you're doing, understand how the medicine is affecting you, and ensure your safety. The total length of your participation would depend on how your body responds to the treatment.